Image Credit: Haberdoedas

fitness culture

Ozempic

weight loss

Ozempic

fitness culture

3Min

South Africa

The “Die” in Diet – GLP-1 medications and medical misuse

With run clubs taking over your neighbourhood and a rise in protein-maxxing, weight loss and fitness culture has taken on a life of its own. A new behemoth however, has recently begun dominating fitness trends; GLP-1s. From Ozempic to Zepbound, GLP-1s have sparked new coversations -and concerns- among many.


From fad diets, chia seeds, run clubs, Pilates, and protein maxxing, weight loss and fitness culture has taken on a life of its own. Recently however, conversations around weight loss are evolving, and requiring more nuance. GLP-1’s, more commonly known by their brand names, Ozempic, Wegovy, Zepbound, Tirzepatide, etc, have enjoyed an uptick in prescription for weight loss, despite little actually being known about drugs and their associated risks. A dearth of research detailing the risks and side-effects posed to patients, surrounds widespread administration and even unprescribed usage of these medications. Research by the National Centre for Biotechnology Information stated that long-term tolerability to, and efficacy of beyond 2 years of treatment are largely unknown. 

Glucagon-like peptide-1 agonists, otherwise known as GLP-1 receptor agonists, Incretin mimetics, or GLP-1 analogues, are medications which help lower blood sugar levels and promote weight loss, with these medications typically being prescribed to patients suffering from Type 2 diabetes or obesity. GLP-1's mimic a naturally occurring hormone in the body (GLP-1), responsible for triggering the release of insulin from the pancreas, blocking Glucagon secretion for elevated blood sugar levels, slowing digestion and subsequently increasing satiety.  

Many who are taking these drugs, are doing so under indiscriminate prescription, resulting in unsuitable candidates who risk experiencing over-restrictive eating patterns, severe food or fluid limitation, diminished food appeal, unusually rapid or excessive and dangerous weight loss, and medical complications such as dehydration-induced renal issues or fluctuating blood glucose levels. Researchers indicate that a primary motivator for taking GLP-1 medication is weight loss, where approximately 35% of people are taking a GLP-1 without medically substantiated reasons and while possessing a normal Body Mass Index (BMI). The research also cites eating disorders as being more common among this cohort.  

While GLP-1 medications do have benefits such as lowering the risk of heart attacks and strokes, helping to slow the progression of kidney failure in people with Type 2 diabetes, assisting with non-alcoholic fatty liver disease, reducing joint pain, sleep apnoea, and food noise; researchers have also noted many alarming risks of taking GLP-1 medications. These risks include pancreatitis, medullary thyroid cancer, acute or sudden kidney injury and worsening diabetes-related retinopathy. Prolonged exposure to these health risks, caution a public health crisis, especially as Medicaid prescriptions for FDA-approved GLP-1 obesity medications observed an increase of more than 546% from 2019 to 2024.  

Alarmingly, the percentage of younger adults - ages 18 to 39 - who were prescribed a GLP-1 drug, also rapidly surged from 2019 to 2024, with an overall increase of 587.8%, signalling an association between youth and mounting self-image crises. Jesse Richards and Sahib Khalsa from the University of Oklahoma cite high-profile celebrity endorsement, popular culture, and consistent advertising to the general public as drivers for a growing societal trend toward broader uses of GLP-1 drugs beyond their traditional medical applications. Along with newer GLP-1 agents like Semaglutide and Tirzepatide respectively showcasing the potential for a loss of up to 15% ~ 20% of total bodyweight, this makes for a highly desirable product among individuals who are trending younger and who are predominantly women, willing to ignore potential side-effects and associated health risks. 

Barbara Fredrickson and Tomi-Ann Roberts from Psychology of Women Quarterly (PWQ) found that habitual body monitoring, eating disorders, and mental health side-effects such as unipolar depression are commonly found among young women and girls who are disproportionately made to suffer the harmful beauty standards enforced by society, further exacerbated by popular culture. This suffering is typically marked by self-objectification through one’s proximity to a standard of attractiveness, with adolescent girls’ and women’s tendency to diet, skip meals, and suffer from eating disorders, increasing as a result.  

Although these medications have the associated benefits of reducing systematic inflammation, lowering the incidence of stroke in individuals with diabetes, and decreasing the likelihood of a major cardiovascular event, they also have the associated side-effects of nausea, vomiting, lack of interest in food, gastroparesis, diarrhoea, and pancreatitis. The promise of weight loss however comes with a caveat however, as studies show that only around 20 % of GLP-1 users will lose the amount of weight loss described in clinical trials, which is around only 15 % of one’s total body weight. Experts advise a more holistic approach to prescribing these medications, with the strict regulation of dispensary, alongside close monitoring and screenings for depression and suicidal ideation among patients experiencing dysmorphic ideation and who are undergoing GLP-1 therapy.  

As GLP-1s become more accessible, studies also highlight how these medications are becoming a luxury, inaccessible to many due to their high price point, lack of broad insurance coverage, and intermittent shortages of the medications. These medications are also not a cure-all as they are not designed to treat psychological conditions, nor to influence negative self-perception. What has therefore saturated the market is a product which treats symptomatically, frequently misused by vulnerable people and often without valid prescriptions.  

Individuals who have for a time observed the desired outcome of these drugs (weight loss), who can no longer afford them, also suffer further from dysmorphic ideation, worsening depressive episodes, and a decline in self-image due to a regaining of weight which had previously been lost. In addition to these potentially disruptive and even fatal side-effects associated with GLP-1 use, these medications often need to be administered indefinitely to maintain desired weight loss. 

Users of the drug also indicated that weight loss associated with GLP-1 use versus diet and exercise suggested that the drugs were negatively perceived as a shortcut and that behavioral changes were perceived as a superior approach to weight loss. Researches who observed these patients, saw that desired weight loss, achieved through GLP-1 use led to a broader disregard among patients, for potentially fatal risks associated with the mechanism of GLP-1 agonists. Associated risks and side-effects of GLP-1 use were reportedly flagged 150 000 times by patients in the United Kingdom, to the Medicines and Healthcare Products Regulatory Agency (MHRA), with more than 100 of these reports resulting in fatalities potentially linked to the drugs. Other sources such as The Independent put deaths linked to GLP-1 use at 150, and Sky News linking over 200 deaths to the drugs.  

One GLP-1 medication in particular, Tirzepatide, was linked to 100 810 adverse reactions as reported by the Yellow Card scheme. While 10 434 cases were classed as serious and 98 with a fatal outcome, the total number of fatality reports is higher, with 120 deaths closely linked to Tirzepatide alone on the MHRA website. Another prolific GLP-1 medication, Semaglutide (Ozempic or Wegovy - made by Novo Nordisk) was mentioned in 44 073 reports of suspected adverse reactions to the drug, through the Yellow Card scheme. Among these cases, gastrointestinal events are by far the most common side-effects associated with these GLP-1 agonists, along with pancreatitis. Tirzepatide, for example had been mentioned in more than 65 000 of these reports, which detailed gastrointestinal events; of these events, 33 had a fatal outcome. 

Reports of these adverse effects from GLP-1s, also predominantly stemmed from women rather than from men. For instance, Tirzepatide accounted for 37 243 reports of adverse effects in women and only 7 306 in men. Of these reports, 79 fatal outcomes were counted among female patients and 34 in male patients. Further research out of the Korea University College of Medicine noted that intense media attention and influencer promotion of GLP-1 medications, coupled with robust marketing tactics, have led to an increase in demand for GLP-1 drugs, ultimately resulting in mass shortages in these medications.  

Photo:The “Die” in Diet – GLP-1 medications and medical misuse  – South African Daily

Image Credit: Jung A Kim & Hye Jin Yoo


Although these medications project only a 15~20% loss in total body weight, Jung A Kim, Hye Jin Yoo find that approximately 40% of the weight loss is derived from a lean body mass, which raises significant concerns for its potential negative impact on skeletal muscle functionality.  

Although GLP-1 medications were initially designed to address health conditions like Type 2 diabetes and obesity, and to improve the quality of life for individuals suffering from these conditions, these drugs have ultimately become attractive to individuals suffering from body dysmorphia, negative self-image and self-objectified ideation amidst the oppressive beauty standards present in popular culture. The broader misuse of these drugs without a proper prescription, leads to vulnerable individuals who are more likely to ignore warnings associated with these medications, in pursuit of personal weight goals and respective weight loss journeys.

Top Contributors

Show more

Explore Topics

Show more

Follow us on social media to engage with breaking stories.

Subscribe to our newsletter for daily updates.

Stay updated on the latest stories shaping South Africa and the world. From politics and business to culture, tech, and finance — we deliver the news in a flash, straight to your inbox.

We don't spam, promised. Only two emails every month, you can opt out anytime with just one click.

Uncover the pulse of South Africa and beyond with SA Daily, your trusted destination for up-to-the-minute news. From breaking local stories to global developments, politics, business, lifestyle, sport, and opinion, we deliver credible and insightful journalism that keeps you informed and engaged with the issues shaping our nation and the world.

We go beyond the headlines with thought-provoking analysis, in-depth features, and diverse perspectives. Guided by accuracy, balance, and relevance, SA Daily empowers readers to navigate an ever-changing news landscape while upholding the highest journalistic standards. Always in the public interest, always for South Africa.

Subscribe to our newsletter for daily updates.

Stay updated on the latest stories shaping South Africa and the world. From politics and business to culture, tech, and finance — we deliver the news in a flash, straight to your inbox.

We don't spam, promised. Only two emails every month, you can opt out anytime with just one click.

Follow us on social media to engage with breaking stories.

Subscribe to our newsletter for daily updates.

Stay updated on the latest stories shaping South Africa and the world. From politics and business to culture, tech, and finance — we deliver the news in a flash, straight to your inbox.

We don't spam, promised. Only two emails every month, you can opt out anytime with just one click.

Uncover the pulse of South Africa and beyond with SA Daily, your trusted destination for up-to-the-minute news. From breaking local stories to global developments, politics, business, lifestyle, sport, and opinion, we deliver credible and insightful journalism that keeps you informed and engaged with the issues shaping our nation and the world.

We go beyond the headlines with thought-provoking analysis, in-depth features, and diverse perspectives. Guided by accuracy, balance, and relevance, SA Daily empowers readers to navigate an ever-changing news landscape while upholding the highest journalistic standards. Always in the public interest, always for South Africa.

Subscribe to our newsletter for daily updates.

Stay updated on the latest stories shaping South Africa and the world. From politics and business to culture, tech, and finance — we deliver the news in a flash, straight to your inbox.

We don't spam, promised. Only two emails every month, you can opt out anytime with just one click.

Follow us on social media to engage with breaking stories.

Subscribe to our newsletter for daily updates.

Stay updated on the latest stories shaping South Africa and the world. From politics and business to culture, tech, and finance — we deliver the news in a flash, straight to your inbox.

We don't spam, promised. Only two emails every month, you can opt out anytime with just one click.

Uncover the pulse of South Africa and beyond with SA Daily, your trusted destination for up-to-the-minute news. From breaking local stories to global developments, politics, business, lifestyle, sport, and opinion, we deliver credible and insightful journalism that keeps you informed and engaged with the issues shaping our nation and the world.

We go beyond the headlines with thought-provoking analysis, in-depth features, and diverse perspectives. Guided by accuracy, balance, and relevance, SA Daily empowers readers to navigate an ever-changing news landscape while upholding the highest journalistic standards. Always in the public interest, always for South Africa.

Subscribe to our newsletter for daily updates.

Stay updated on the latest stories shaping South Africa and the world. From politics and business to culture, tech, and finance — we deliver the news in a flash, straight to your inbox.

We don't spam, promised. Only two emails every month, you can opt out anytime with just one click.

Follow us on social media to engage with breaking stories.

Subscribe to our newsletter for daily updates.

Stay updated on the latest stories shaping South Africa and the world. From politics and business to culture, tech, and finance — we deliver the news in a flash, straight to your inbox.

We don't spam, promised. Only two emails every month, you can opt out anytime with just one click.

Uncover the pulse of South Africa and beyond with SA Daily, your trusted destination for up-to-the-minute news. From breaking local stories to global developments, politics, business, lifestyle, sport, and opinion, we deliver credible and insightful journalism that keeps you informed and engaged with the issues shaping our nation and the world.

We go beyond the headlines with thought-provoking analysis, in-depth features, and diverse perspectives. Guided by accuracy, balance, and relevance, SA Daily empowers readers to navigate an ever-changing news landscape while upholding the highest journalistic standards. Always in the public interest, always for South Africa.

Subscribe to our newsletter for daily updates.

Stay updated on the latest stories shaping South Africa and the world. From politics and business to culture, tech, and finance — we deliver the news in a flash, straight to your inbox.

We don't spam, promised. Only two emails every month, you can opt out anytime with just one click.